CN Patent

CN103626742B — 激酶的联-芳基间-嘧啶抑制剂

Assigned to Biomedical impact company · Expires 2017-04-26 · 9y expired

What this patent protects

本发明提供了具有一般结构(A)的联芳间‑嘧啶化合物。本发明的嘧啶化合物能够抑制激酶，诸如Jak激酶家族中的成员和各种其它特异性受体和非‑受体激酶。

USPTO Abstract

本发明提供了具有一般结构(A)的联芳间‑嘧啶化合物。本发明的嘧啶化合物能够抑制激酶，诸如Jak激酶家族中的成员和各种其它特异性受体和非‑受体激酶。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN103626742B
Jurisdiction: CN
Classification: —
Expires: 2017-04-26
Drug substance claim: No
Drug product claim: No
Assignee: Biomedical impact company
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.